Trial reportBioMed research international2014
Evaluation of the efficacy of 50% autologous serum eye drops in different ocular surface pathologies.
Trial report in BioMed research international, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06242860 (A Prospective, Clinical Trial Eye Lipid Mobilizer), which is not on this map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Prospective, Clinical Trial Eye Lipid Mobilizer (ELM) Using Heat and Vibration for the Treatment of Meibomian Gland Dysfunction (MGD)
Who cites it
27 citing papers in PubMed, 79 citations in OpenAlex.
- Comparative evaluation of effectiveness of twenty versus fifty percent autologous serum eye drops in treatment of dry eye.Indian journal of ophthalmology · 2023Trial
- Allogeneic and autologous serum eye drops: a pilot double-blind randomized crossover trial.Acta ophthalmologica · 2021Trial
- Sterile peripheral corneal infiltration mimicking infectious keratitis following chemical injury: a case report.BMC ophthalmology · 2026Article
- Microbial Assessment of Reclosable Single-Day Use Ophtioles Containing Autologous Serum Eye Drops.Bioengineering (Basel, Switzerland) · 2026Article
- Autologous blood in the management of ocular surface disorders.World journal of experimental medicine · 2024Review
- Review
- The use of rh-NGF in the management of neurotrophic keratopathy.Frontiers in ophthalmology · 2024Review
- Current Advances in Regenerative Strategies for Dry Eye Diseases: A Comprehensive Review.Bioengineering (Basel, Switzerland) · 2023Review
- Combination of Bandage Contact Lens and Autologous Serum Eye Drop for the Treatment of Superior Limbic Keratoconjunctivitis.Clinical optometry · 2023Article
- Therapeutic Hyper-CL soft contact lens in Sjögren's syndrome.American journal of ophthalmology case reports · 2022Article
- Immunomodulatory Role of Neuropeptides in the Cornea.Biomedicines · 2022Review
- The impact of sensory neuropathy and inflammation on epithelial wound healing in diabetic corneas.Progress in retinal and eye research · 2022Review
- New Pharmacological Approaches for the Treatment of Neurotrophic Keratitis.Frontiers in pharmacology · 2022Review
- The Limbal Niche and Regenerative Strategies.Vision (Basel, Switzerland) · 2021Review
- Management Strategies of Ocular Chemical Burns: Current Perspectives.Clinical ophthalmology (Auckland, N.Z.) · 2020Review
- The use of autologous serum eye drops for the treatment of ocular surface disorders.European journal of hospital pharmacy : science and practice · 2019Article
- Strategies for reconstructing the limbal stem cell niche.The ocular surface · 2019Review
- Emerging Approaches for Ocular Surface Regeneration.Current ophthalmology reports · 2019Article
- Improvement of chronic corneal opacity in ocular surface disease with prosthetic replacement of the ocular surface ecosystem (PROSE) treatment.American journal of ophthalmology case reports · 2018Article
- The corneal epitheliotrophic abilities of lyophilized powder form human platelet lysates.PloS one · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study evaluated the efficacy of 50% autologous serum eye drops in ocular surface diseases not improved by conventional therapy.
methodsWe analyzed two groups: (1) acute eye pathologies (e.g., chemical burns) and (2) chronic eye pathologies (e.g., recurrent corneal erosion, neurotropic keratitis, and keratoconjunctivitis sicca). The patients were treated for surface instability after conventional therapy. The patients received therapy 5 times a day until stabilization of the framework; they then reduced therapy to 3 times a day for at least 3 months. We analyzed the best corrected visual acuity, epithelial defects, inflammation, corneal opacity, and corneal neovascularization. We also analyzed symptoms such as tearing, burning, sense of foreign body or sand, photophobia, blurred vision, and difficulty opening the eyelids.
resultsWe enrolled 15 eyes in group 1 and 11 eyes in group 2. The average therapy period was 16 ± 5.86 weeks in group 1 and 30.54 ± 20.33 weeks in group 2. The epithelial defects all resolved. Signs and symptoms improved in both groups. In group 2, the defect recurred after the suspension of therapy in 2 (18%) patients; in group 1, no defects recurred.
conclusionsAutologous serum eye drops effectively stabilize and improve signs and symptoms in eyes previously treated with conventional therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.